Table 4.
Treatments during hospitalisation and before discharge
| COVID-19 pandemic period cohort (n=398) | Historical control cohort (n=384) | p value | ||
|---|---|---|---|---|
| Any rescue therapy | 177/387 (46%) | 134/373 (36%) | 0·0064 | |
| Infliximab | 124/176 (70%) | 106/133 (80%) | 0·021* | |
| Adalimumab | 1/176 (1%) | 3/133 (2%) | .. | |
| Ciclosporin | 11/176 (6%) | 11/133 (8%) | .. | |
| Tofacitinib | 13/176 (7%) | 3/133 (2%) | .. | |
| Ustekinumab | 7/176 (4%) | 0 | .. | |
| Vedolizumab | 20/176 (11%) | 10/133 (8%) | .. | |
| Data not available | 1 | 1 | ||
| Dose of infliximab (mg/kg) | .. | .. | 0·40 | |
| 10 | 27/115 (23%) | 17/92 (18%) | .. | |
| 5 | 88/115 (77%) | 75/92 (82%) | .. | |
| Second dose of infliximab given before discharge | 23/120 (19%) | 24/104 (23%) | 0·51 | |
Data are n/N (%).
*
Comparison of which drug was given as rescue therapy in each cohort (ie, the proportion of patients receiving each type of rescue therapy was significantly different between the two groups).